Please login to the form below

Not currently logged in

Arena/ Eisai's lorcaserin shows efficacy

Weight loss drug lorcaserin, co-marketed by Arena and Eisai, has met efficacy goals in a phase III trial involving type 2 diabetes patients

Weight loss drug lorcaserin has met efficacy goals in a phase III trial involving obese and overweight patients with type 2 diabetes.

The drug, which is co-marketed by Arena Pharmaceuticals and Eisai following an agreement in July 2010,  met all three co-primary efficacy endpoints in the BLOOM-DM (Behavioural modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) study, with significant weightloss recorded in patients following a year's treatment.

The study compared  lorcaserin to placebo, with over 604 participants affected by type 2 diabetes involved. Lorcaserin is developed for weight management in obese or overweight patients with at least one ongoing weight-related condition.

Adverse effects recorded in the study included headaches, upper respiratory infection and backpain. Hypoglycaemia related effects were also reported by 29.3 per cent of patients taking lorcaserin 10mg BID, compared to 21.0 per cent of patients on placebo.  No events of severe hypoglycaemia were reported in either treatment group, however.

Earlier this year, the US Food and Drug Administration (FDA) rejected a new drug application (NDA) for lorcaserin filed by Arena, with the regulatory body citing insufficient evidence of efficacy, as well as safety concerns for its decision.

In its complete response letter denying approval for the drug, however, the FDA recommended that Arena submit the final study report of the BLOOM-DM trial.

Speaking on the potential effects of the trial results Jack Lief, president and CEO, Arena, said: "We look forward to reviewing the BLOOM-DM data with the FDA as the efficacy results are aligned with the agency's categorical benchmark for weight management."

9th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...